Compare Amphastar Pharmaceuticals Inc (AMPH) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Extra Space Storage, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Extra Space Storage, Inc. trades at $145.13 (market cap $30.41B). The key difference: Extra Space Storage, Inc. is far larger — about 36.8× Amphastar Pharmaceuticals Inc's market cap, and Extra Space Storage, Inc. pays a 4.5% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | EXR | |
|---|---|---|
Market Cap | $826.08M | $30.41B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $152.75 |
52-Week Low | $16.87 | $126.67 |
Enterprise Value | $1.22B | $44.21B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Extra Space Storage (EXR) trades at $143.96, up 0.9% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $3.38B and net income of $974M, though profitability margins have moderated from prior peaks. Recent news includes a $550M senior notes offering and the release of its 2025 sustainability report, indicating ongoing capital management and operational focus.
Outlook is mixed: analyst consensus is a Buy with a $155.88 price target, but technical weakness and expense growth pose near-term risks. The stock offers income via a $1.62 dividend, yet investors face headwinds from competitive pressures and potential occupancy declines. Valuation remains elevated with a P/E of 32.35, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
